Literature DB >> 17640990

Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia.

T C Nichols1, W H Busby, E Merricks, J Sipos, M Rowland, K Sitko, D R Clemmons.   

Abstract

IGF-I has been shown to play a role in the progression of atherosclerosis in experimental animal models. IGF-binding protein-4 (IGFBP-4) binds to IGF-I and prevents its association with receptors. Overexpression of a protease-resistant form of IGFBP-4 has been shown to inhibit the ability of IGF-I to stimulate normal smooth muscle cell growth in mice. Based on these observations, we prepared a protease-resistant form of IGFBP-4 and infused it into hypercholesterolemic pigs. Infusion of the protease-resistant mutant inhibited lesion development by 53.3 +/- 6.1% (n = 6; P < 0.01). Control vessels that received an equimolar concentration of IGF-I and the protease-resistant IGFBP-4 showed no reduction in lesion size compared with control lesions that were infused with vehicle. Infusion of a nonmutated form of IGFBP-4 did not significantly inhibit lesion development. Proliferating cell nuclear antigen analysis showed that the mutant IGFBP-4 appeared to inhibit cell proliferation. The area occupied by extracellular matrix was also reduced proportionally compared with total lesion area. Immunoblotting revealed that the mutant IGFBP-4 remained intact, whereas the wild-type IGFBP-4 that was infused was proteolytically cleaved. Further analysis of the lesions revealed that a marker protein, IGFBP-5, whose synthesis is stimulated by IGF-I, was decreased in the lesions that received the protease-resistant, IGFBP-4 mutant, whereas there was no change in lesions that received wild-type IGFBP-4 or the mutant protein plus IGF-I. These findings clearly illustrate that infusion of protease-resistant IGFBP-4 into the perilesion environment results in inhibition of cell proliferation and attenuation of the development of neointima. The findings support the hypothesis that inhibiting IGFBP-4 proteolysis in the lesion microenvironment could be an effective means for regulating neointimal expansion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640990     DOI: 10.1210/en.2007-0571

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Authors:  Laura A Maile; Walker H Busby; Timothy C Nichols; Dwight A Bellinger; Elizabeth P Merricks; Michael Rowland; Umadevi Veluvolu; David R Clemmons
Journal:  Sci Transl Med       Date:  2010-02-10       Impact factor: 17.956

2.  Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability.

Authors:  Shaw-Yung Shai; Sergiy Sukhanov; Yusuke Higashi; Charlotte Vaughn; James Kelly; Patrice Delafontaine
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07-29       Impact factor: 8.311

Review 3.  Aging, atherosclerosis, and IGF-1.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-04-05       Impact factor: 6.053

4.  IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestine.

Authors:  Kaori Austin; Nuvair A Imam; John E Pintar; Patricia L Brubaker
Journal:  Endocrinology       Date:  2014-12-16       Impact factor: 4.736

Review 5.  IGF-1, oxidative stress and atheroprotection.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  Trends Endocrinol Metab       Date:  2010-01-12       Impact factor: 12.015

Review 6.  Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging.

Authors:  Yusuke Higashi; Henry C Quevedo; Summit Tiwari; Sergiy Sukhanov; Shaw-Yung Shai; Asif Anwar; Patrice Delafontaine
Journal:  Front Horm Res       Date:  2014-06-10       Impact factor: 2.606

7.  ARFI imaging for noninvasive material characterization of atherosclerosis. Part II: toward in vivo characterization.

Authors:  Russell H Behler; Timothy C Nichols; Hongtu Zhu; Elizabeth P Merricks; Caterina M Gallippi
Journal:  Ultrasound Med Biol       Date:  2008-11-21       Impact factor: 2.998

8.  Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo.

Authors:  Yun Ning; Alwin G P Schuller; Cheryl A Conover; John E Pintar
Journal:  Mol Endocrinol       Date:  2008-02-07

9.  Comparative endocrinology of aging and longevity regulation.

Authors:  John B Allard; Cunming Duan
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-23       Impact factor: 5.555

10.  Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.

Authors:  A J Ryan; S Napoletano; P A Fitzpatrick; C A Currid; N C O'Sullivan; J H Harmey
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.